Last --
Change Today 0.00 / 0.00%
Volume 0.0
STDAY On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel-unspn adr (STDAY) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
06/20/14
P/E TM
--
Dividend
$0.89
Dividend Yield
--
Current Stock Chart for STADA ARZNEIMITTEL-UNSPN ADR (STDAY)

Related News

No related news articles were found.

stada arzneimittel-unspn adr (STDAY) Related Businessweek News

No Related Businessweek News Found

stada arzneimittel-unspn adr (STDAY) Details

STADA Arzneimittel Aktiengesellschaft is engaged in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates primarily in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including stomach medicines, antihypertensive agents, and anti-inflammatory agents. This segment’s primarily products include Phospholipide, a liver medicine; Diclofenac, an antirheumatic drug; Tilidine, an opioid; Enalapril, an ACE inhibitor; and Omeprazole, a stomach medicine. The Branded Products segment provides non-prescription products. This segment’s primarily products comprise Grippostad, a cold medicine; Apo-Go, a Parkinson medicine; Snup, a nasal preparation; Zaldiar, a pain medicine; Chondroxid for the treatment of degenerative joint diseases; and Ladival, a sun cream. The company has license and collaboration agreements with Gedeon Richter Plc for the development and marketing of biosimilar products for two monoclonal antibodies rituximab and optionally trastuzumab. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. STADA Arzneimittel Aktiengesellschaft was founded in 1895 and is headquartered in Bad Vilbel, Germany.

10,076 Employees
Last Reported Date: 04/30/14
Founded in 1895

stada arzneimittel-unspn adr (STDAY) Top Compensated Officers

Chairman of the Executive Board and Chief Exe...
Total Annual Compensation: €3.2M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €1.4M
Chief Business Development & Central Services...
Total Annual Compensation: €844.6K
Compensation as of Fiscal Year 2013.

stada arzneimittel-unspn adr (STDAY) Key Developments

STADA AG Presents at 2014 Russian Pharmaceutical Forum, Jun-17-2014 02:55 PM

STADA AG Presents at 2014 Russian Pharmaceutical Forum, Jun-17-2014 02:55 PM. Venue: Corinthia Saint-Petersburu Hotel, 57 Nevskij Prospect, St. Petersburg, Russia. Speakers: Dmitriy Efimov, Senior Vice President for Russia, CIS and South East Europe.

Stada-Arzneimittel AG Approves Dividend for 2013

Stada-Arzneimittel AG announced that at the AGM held on June 4, 2014, the shareholders approved dividend of EUR 0.66 per common share, which is significantly higher than the previous year by 32%, with the remaining surplus being carried forward.

Stada-Arzneimittel AG Reports Earnings Results for the First Quarter Ended March 31, 2014; Confirms Outlook for Financial Year 2014

Stada-Arzneimittel AG reported earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported group sales of EUR 507.4 million against EUR 473.2 million for the same period last year. Operating profit was EUR 63.1 million against EUR 70.0 million for the same period last year. Adjusted operating profit was EUR 87.6 million against EUR 71.9 million for the same period last year. EBITDA was EUR 97.7 million against EUR 96.6 million for the same period last year. Adjusted EBITDA was EUR 114.7 million against EUR 98.2 million for the same period last year. Net income was EUR 35.0 million or EUR 0.58 earning per share against EUR 34.9 million or EUR 0.59 per share for the same period last year. Adjusted net income was EUR 52.6 million or EUR 0.87 per share adjusted against EUR 36.7 million or EUR 0.62 per share adjusted for the same period last year. The company confirmed outlook for financial year 2014. For the year, the company expects slight growth in group sales, adjusted EBITDA and adjusted net income.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STDAY:US $0.00 USD 0.00

STDAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 630.00 GBp +19.00
Richter Gedeon Nyrt 4,247 +23.00
Impax Laboratories Inc $29.03 USD +0.11
Skyepharma PLC 247.75 GBp -1.25
Vernalis PLC 32.00 GBp +0.125
View Industry Companies
 

Industry Analysis

STDAY

Industry Average

Valuation STDAY Industry Range
Price/Earnings 16.7x
Price/Sales 1.0x
Price/Book 2.1x
Price/Cash Flow 16.6x
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL-UNSPN ADR, please visit www.stada.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.